Literature DB >> 28411086

Early depletion of CA1 neurons and late neurodegeneration in a mouse tauopathy model.

Lone Helboe1, Jan Egebjerg1, Pernille Barkholt2, Christiane Volbracht3.   

Abstract

Alzheimer's disease (AD) and tauopathies, such as frontotemporal dementia (FTD), are characterized by formation of neurofibrillary tangles consisting of hyperphosphorylated tau. Further neuropathological characteristics include synaptic loss, neurodegeneration and brain atrophy. Here, we explored the association between hyperphosphorylated tau species, brain atrophy, synaptic and neuronal loss in a mouse model (rTg4510) carrying the human tau (hTau) P301L mutation found in a familiar form of FTD. We established that hTau expression during the first 6 postnatal weeks was important for the progression of tauopathy in rTg4510 mice. Short term suppression of postnatal hTau expression delayed the onset of tau pathology by approximately 6months in this model. Early postnatal hTau expression was detrimental to CA1 neurons of the hippocampus and reduced neuronal numbers in 6-10weeks young rTg4510 mice prior to the appearance of hyperphosphorylated hTau species in the hippocampus. Hyperphosphorylated hTau species emerged from 10 to 24weeks of age and were associated with increased ubiquitin levels, gliosis, and brain atrophy and preceded the synaptic loss and CA1 neurodegeneration that occurred at 48weeks of age. We present two consequences of hTau expression in CA1 in rTg4510 mice: an early decrease in neuron number already established prior to the presence of hyperphosphorylated tau species and a later neurodegeneration dependent on hyperphosphorylated tau. Neurodegeneration and synaptic protein loss were completely prevented when hTau expression was suppressed prior to the appearance of hyperphosphorylated tau species. Suppression of hTau expression after the onset of tau hyperphosphorylation and tangle pathology initiated at 16weeks partially rescued neuronal loss at 48weeks of age, while a reduction of neurodegeneration was no longer possible when hTau suppression was introduced as late as at 24weeks of age. Our results in rTg4510 mice argue that it is promising to lower hyperphosphorylated tau species at early stages of tau pathology to protect from neurodegeneration.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alzheimer’s disease; Hyperphosphorylated tau; Neurodegeneration; Tauopathy; rTg4510 mice

Mesh:

Substances:

Year:  2017        PMID: 28411086     DOI: 10.1016/j.brainres.2017.04.002

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  14 in total

1.  Developmental Pathogenicity of 4-Repeat Human Tau Is Lost with the P301L Mutation in Genetically Matched Tau-Transgenic Mice.

Authors:  Julia E Gamache; Lisa Kemper; Elizabeth Steuer; Kailee Leinonen-Wright; Jessica M Choquette; Chris Hlynialuk; Kellie Benzow; Keith A Vossel; Weiming Xia; Michael D Koob; Karen H Ashe
Journal:  J Neurosci       Date:  2019-11-04       Impact factor: 6.167

2.  GFP-Mutant Human Tau Transgenic Mice Develop Tauopathy Following CNS Injections of Alzheimer's Brain-Derived Pathological Tau or Synthetic Mutant Human Tau Fibrils.

Authors:  Garrett S Gibbons; Rachel A Banks; Bumjin Kim; Hong Xu; Lakshmi Changolkar; Susan N Leight; Dawn M Riddle; Chi Li; Ronald J Gathagan; Hannah J Brown; Bin Zhang; John Q Trojanowski; Virginia M-Y Lee
Journal:  J Neurosci       Date:  2017-10-06       Impact factor: 6.167

3.  Impaired Kv7 channel function in cerebral arteries of a tauopathy mouse model (rTg4510).

Authors:  Inge E M de Jong; Thomas A Jepps
Journal:  Physiol Rep       Date:  2018-12

4.  Differences in hippocampal subfield volume are seen in phenotypic variants of early onset Alzheimer's disease.

Authors:  Thomas D Parker; Catherine F Slattery; Keir X X Yong; Jennifer M Nicholas; Ross W Paterson; Alexander J M Foulkes; Ian B Malone; David L Thomas; David M Cash; Sebastian J Crutch; Nick C Fox; Jonathan M Schott
Journal:  Neuroimage Clin       Date:  2018-12-11       Impact factor: 4.881

5.  Antibody-mediated clearance of tau in primary mouse microglial cultures requires Fcγ-receptor binding and functional lysosomes.

Authors:  Christian Rungsted Andersson; Jeppe Falsig; Jeffrey B Stavenhagen; Søren Christensen; Fredrik Kartberg; Nina Rosenqvist; Bente Finsen; Jan Torleif Pedersen
Journal:  Sci Rep       Date:  2019-03-15       Impact factor: 4.379

6.  Factors other than hTau overexpression that contribute to tauopathy-like phenotype in rTg4510 mice.

Authors:  Julia Gamache; Kellie Benzow; Colleen Forster; Lisa Kemper; Chris Hlynialuk; Eva Furrow; Karen H Ashe; Michael D Koob
Journal:  Nat Commun       Date:  2019-06-06       Impact factor: 14.919

7.  Inhibition of Tau aggregation with BSc3094 reduces Tau and decreases cognitive deficits in rTg4510 mice.

Authors:  Marta Anglada-Huguet; Sara Rodrigues; Katja Hochgräfe; Eckhard Mandelkow; Eva-Maria Mandelkow
Journal:  Alzheimers Dement (N Y)       Date:  2021-06-01

8.  Differences in Synaptic Dysfunction Between rTg4510 and APP/PS1 Mouse Models of Alzheimer's Disease.

Authors:  Simon Gelman; Jonathan Palma; Geoffrey Tombaugh; Afshin Ghavami
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

9.  Highly specific and selective anti-pS396-tau antibody C10.2 targets seeding-competent tau.

Authors:  Nina Rosenqvist; Ayodeji A Asuni; Christian R Andersson; Søren Christensen; Justus A Daechsel; Jan Egebjerg; Jeppe Falsig; Lone Helboe; Pia Jul; Fredrik Kartberg; Lars Ø Pedersen; Einar M Sigurdsson; Florence Sotty; Karsten Skjødt; Jeffrey B Stavenhagen; Christiane Volbracht; Jan T Pedersen
Journal:  Alzheimers Dement (N Y)       Date:  2018-10-14

10.  Pathogenic tau does not drive activation of the unfolded protein response.

Authors:  Aleksandra P Pitera; Ayodeji A Asuni; Vincent O'Connor; Katrin Deinhardt
Journal:  J Biol Chem       Date:  2019-05-03       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.